Examining Clinical Factors Pre and Post Biofire BCID Implementation
Session Number
Project ID: MEDH 27
Advisor(s)
Dr. Janna Lynn Williams; Northwestern University, Division of Infectious Disease
Discipline
Medical and Health Sciences
Start Date
19-4-2023 10:50 AM
End Date
19-4-2023 11:05 AM
Abstract
Bloodstream infections (BSI) represent approximately 40% of hospital-acquired (HA) cases and 20% of ICU-acquired cases. Furthermore, bloodstream infections are known to be associated with higher mortality, as one study showed a 14% increase in mortality in HIV patients with positive blood cultures. Due to the widespread susceptibility to BSIs, it requires a way to properly and quickly diagnose and identify the correct antibiotic for medication. So, beginning in 2021, Northwestern University Hospitals in the Chicagoland area began to switch to Biofire Blood Culture Identification 2 (BCID2) in order to better analyze these blood samples in a quicker time frame. This investigation examined clinical factors such as length of stay, mortality, and accurate decision of antibiotic both before and after implementation of BCID2 in hospitals. After analyzing one-hundred patient charts (fifty pre and post implementation), the research showed that while the length of stay and accurate antibiotic determination is roughly similar pre and post implementation, other clinical factors greatly improved post- implementation. For example, time between blood culture order and test result as well as time between blood culture order and correct antibiotic determination decreased significantly under BCID2. However, a greater number of samples should be analyzed before a final decision is made regarding the efficacy of BCID2.
Examining Clinical Factors Pre and Post Biofire BCID Implementation
Bloodstream infections (BSI) represent approximately 40% of hospital-acquired (HA) cases and 20% of ICU-acquired cases. Furthermore, bloodstream infections are known to be associated with higher mortality, as one study showed a 14% increase in mortality in HIV patients with positive blood cultures. Due to the widespread susceptibility to BSIs, it requires a way to properly and quickly diagnose and identify the correct antibiotic for medication. So, beginning in 2021, Northwestern University Hospitals in the Chicagoland area began to switch to Biofire Blood Culture Identification 2 (BCID2) in order to better analyze these blood samples in a quicker time frame. This investigation examined clinical factors such as length of stay, mortality, and accurate decision of antibiotic both before and after implementation of BCID2 in hospitals. After analyzing one-hundred patient charts (fifty pre and post implementation), the research showed that while the length of stay and accurate antibiotic determination is roughly similar pre and post implementation, other clinical factors greatly improved post- implementation. For example, time between blood culture order and test result as well as time between blood culture order and correct antibiotic determination decreased significantly under BCID2. However, a greater number of samples should be analyzed before a final decision is made regarding the efficacy of BCID2.